Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer's Disease and Other Neurological ConditionsBusiness Wire • 10/23/26
Tempus AI: Moderna's New Cancer Vaccine Partner Is The Pick Of The AI Biotech BunchSeeking Alpha • 10/23/26
The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are WinningMarketBeat • 10/19/26
Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLCBusiness Wire • 10/19/26
Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare DiseasesBusiness Wire • 10/13/26
Tempus AI Expands Strategic Collaborations to Drive Future GrowthZacks Investment Research • 10/12/26
Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026Business Wire • 10/01/26
Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral RegurgitationBusiness Wire • 09/28/26
Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4Zacks Investment Research • 09/24/26